Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC) Meeting Abstract
| Authors: | O'Reilly, E. M.; Sahai, V.; Bendell, J. C.; Bullock, A. J.; LoConte, N. K.; Hatoum, H.; Ritch, P. S.; Hool, H.; Leach, J. W.; Sanchez, J.; Sohal, D.; Strickler, J. H.; Patel, R.; Wang-Gillam, A.; Firdaus, I.; Kapoun, A. M.; Holmgren, E.; Zhou, L.; Dupont, J.; Picozzi, V. J. |
| Abstract Title: | Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC) |
| Meeting Title: | 2017 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2017 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-02-01 |
| Language: | English |
| ACCESSION: | WOS:000443281700272 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2017.35.4_suppl.279 |
| Notes: | Meeting Abstract: 279 -- Source: Wos |
